MAPT and Alzheimer disease: Pharmacological inhibition of sEH in 5xFAD mice and TgF344-AD rats reduced Aβ burden, tau pathology, biomarkers of inflammation, ROS, and endoplasmic reticulum stress and improved cognitive dysfunction [262–264].